替米沙坦对原发性高血压病患者降钙素基因相关肽血浆浓度的影响

目的探讨血管紧张素Ⅱ受体拮抗剂替米沙坦对轻、中度高血压病患者的降压作用及其对血浆降钙素基因相关肽（CGRP）水平的影响。方法 150例高血压病患者接受替米沙坦治疗4周,剂量80 mg/d。采用自身前后对比方法 ,分别于治疗前、治疗中（服药5 d）、治疗后（服药30 d）测定血浆内皮素（ET）、CGRP浓度。结果原发性高血压患者经治疗后5 d、30 d血压均较治疗前显著下降（P〈0.01）,同时血浆ET浓度下降,降钙素基因相关肽浓度均显著升高（P〈0.01）,血压的下降幅度与血浆降钙素基因相关肽浓度呈显著负相关（r=-0.556,P=0.006）。结论替米沙坦能显著降低轻、中度高血压患者的血压,同时能升高血浆降钙素基因相关肽浓度;替米沙坦促进降钙素基因相关肽释放可能是其降压机制之一。

Effect of telmisartan on the plasma level of calcitonin gene-related peptide in patients with essential hypertension

Objective： To investigate the antihypertensive effect of telmisartan,an inhibitor of angiotensin Ⅱ receptor,and its effect on the plasma calcitionin gene-related peptide（CGRP） concentration in patients with mild or moderate essential hypertension.Methods： One hundred and fifty patients with mild or moderate essential hypertension were treated with telmisartan,80 mg/d,given orally for 4 weeks.Blood pressure and plasma concentrations of endothelin and CGRP were measured.Results： In patients with mild or moderate essential hypertension,telmisartan significantly decreased blood pressure 5 days and 30 days after treatment（P0.01） concomitantly with an increase in plasma concentrations of CGRP（P0.01） and decreased the plasma concentrations of endothelin.And there was a negative correlation between the decrease of blood pressure and increase of plasma concentration of CGRP.Conclusion： Telmisartan can significantly treat mild or moderate essential hypertension concomitantly with an increase of plasma concentrations of CGRP,and the antihypertensive effect of telmisartan may be related to the simulation of CGRP release.